文献速递肝病

肠促胰岛素(GLP-1受体激动剂及双/三重激动剂)与肝脏

Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver.
PubMed 文献 · J Hepatol · 2023-08-09

本文综述了GLP-1受体激动剂及与胰高血糖素和/或葡萄糖依赖性促胰岛素多肽(GIP)激动剂联合应用在代谢功能障碍相关脂肪性肝炎(MASH)中的研究进展。GLP-1受体激动剂已进入III期临床试验,联合治疗在体重、胰岛素抵抗和非侵入性肝脏参数方面有改善证据。其直接作用与通过改善体重和胰岛素抵抗的间接作用仍有争议,联合治疗的疗效提升需权衡副作用负担、药物相互作用和成本。

要点

  • GLP-1受体激动剂已进入MASH的III期临床试验。
  • 与胰高血糖素和/或GIP激动剂的联合治疗在体重、胰岛素抵抗和非侵入性肝脏参数方面有改善证据。
  • GLP-1受体激动剂对MASH的直接独立作用与通过改善体重和胰岛素抵抗的间接作用仍有争议。

核心结论

  • GLP-1受体激动剂已进入MASH的III期临床试验,联合治疗在相关患者中显示体重、胰岛素抵抗和非侵入性肝脏参数的改善证据。
  • GLP-1受体激动剂对MASH是否有直接独立作用,还是通过改善体重、胰岛素抵抗和血糖控制影响病理生理,仍有争议。
  • 联合治疗需权衡疗效提升与累积副作用负担、潜在药物相互作用和成本。
  • 胰高血糖素与GIP激动相对于GLP-1激动的 optimal 比例尚不确定,GIP激动或拮抗哪种更优也不确定。
  • 鉴于肠激素激动剂主要作用可能在上游的体重环节,初始联合可能聚焦于对纤维化有更直接作用的药物,包括FGF21和pan-PPAR激动剂。

研究设计与样本

  • 本文为综述,检索范围原文未报告。

主要发现

  • GLP-1受体激动剂是首批在MASH患者中评估的药物类型之一,成功的IIa和IIb期研究已推动其进入III期临床试验。
  • 与胰高血糖素激动剂和/或GIP激动剂联合的新方案已在相关患者群体中探索,有证据显示体重、胰岛素抵抗和非侵入性肝脏参数改善。
  • 联合治疗正在探索中,但疗效提升需与累积副作用负担、潜在药物相互作用和成本权衡。
  • 胰高血糖素和GIP激动相对于GLP-1激动的 optimal 比例尚不确定,GIP激动或拮抗哪种是最佳策略也不确定。
  • 存在多种将肠激素激动剂与该领域其他新兴药物联合的假设性组合。

关键数值与推荐

  • 原文未报告具体数值标准或推荐条款。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The principle pathological drivers of metabolic dysfunction-associated steatohepatitis (MASH) are obesity and associated insulin resistance, rendering them key therapeutic targets. As glucagon-like peptide 1 receptor agonists (GLP-1RAs) have been licensed for the treatment of diabetes and obesity, they were one of the first drug types to be evaluated in patients with MASH, and successful phase IIa and IIb studies have resulted in progression to phase III clinical trials. Alongside GLP-1RAs, newer combinations with glucagon agonists and/or glucose-dependent insulinotropic peptide (GIP) agonists have been explored in related patient groups, with evidence of improvements in weight, insulin resistance and non-invasive liver parameters. Whether GLP-1RAs have direct, independent effects on MASH or whether they impact on pathophysiology through improvements in weight, insulin resistance and glycaemic control remains a matter of debate. Combinations are being explored, although the potential improvement in efficacy will need to be weighed against the cumulative side-effect burden, potential drug-drug interactions and costs. There is also uncertainty regarding the optimal ratio of glucagon and GIP agonism to GLP-1 agonism in combination agents, and as to whether GIP agonism or antagonism is the optimal approach. Finally, there are also multiple hypothetical permutations combining gut hormone agonists with other emerging assets in the field. Given that the likely dominant mode of action of gut hormone agonists is upstream on weight, initial combinations might focus on agents which have been shown to have a more direct effect on fibrosis, which would include FGF21 and pan-PPAR agonists.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Newsome PN, Ambery P. Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver. J Hepatol. 2023. PMID: 37562748. doi:10.1016/j.jhep.2023.07.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。